首页> 外文期刊>Journal of intensive care medicine >Effects of Inotropes on the Mortality in Patients With Septic Shock
【24h】

Effects of Inotropes on the Mortality in Patients With Septic Shock

机译:仪镜对脓乳液休克患者死亡率的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Although surviving sepsis campaign guidelines recommend the use of inotropes in the presence of myocardial dysfunction, the effects of inotropes, including epinephrine, dobutamine, and milrinone, on in-hospital mortality in patients with septic shock remains unclear. Materials and Methods: We conducted an international,2-center, retrospective cohort study. The Cox proportional hazards regression model with time-varying covariates was used to investigate whether epinephrine, milrinone, or dobutamine reduces in-hospital mortality in patients with septic shock. Sensitivity analysis was performed using propensity score matching. The primary outcome was in-hospital mortality. The secondary outcome included atrial fibrillation (Afib) with a rapid ventricular response (RVR) in the intensive care unit (ICU) and ICU-free days. Results: A total of 417 patients with septic shock were included, 72 (17.3%) of whom received inotropes. The use of epinephrine and dobutamine was associated with significantly higher in-hospital mortality (epinephrine, hazard ratio [HR]: 4.79, 95% confidence interval [CI]: 2.12-10.82, P = .001; dobutamine, HR: 2.53, 95% CI: 1.30-4.95, P = .046). The effects of epinephrine and dobutamine were time- and dose-dependent. The use of milrinone was not associated with increased mortality (HR: 1.07, 95% CI: 0.42-2.68, P = .345). The use of epinephrine, dobutamine, and milrinone was associated with significantly increased odds of Afib with RVR (epinephrine, odds ratio [OR]: 3.88, 95% CI: 1.11-13.61, P = .034; dobutamine, OR: 3.95, 95% CI: 1.14-13.76; and milrinone, OR: 3.77, 95% CI: 1.05-13.59). On the other hand, the use of epinephrine, dobutamine, and milrinone was not associated with less ICU-free days (epinephrine, adjusted OR: 0.30, 95% CI: 0.09-1.01, P = .053; dobutamine, adjusted OR: 0.91, 95% CI: 0.29-2.84; and milrinone, adjusted OR: 0.60, 95% CI: 0.19-1.87). Conclusion: The present study showed that the use of epinephrine and dobutamine was associated with significantly increased in-hospital mortality in patients with septic shock. These effects were both time- and dose-dependent. On the other hand, the use of milrinone was not associated with increased in-hospital mortality.
机译:背景:尽管存活败血症运动指南建议在存在心肌功能障碍的情况下使用肌力药物,但肌力药物(包括肾上腺素、多巴酚丁胺和米力农)对败血症休克患者住院死亡率的影响尚不清楚。材料和方法:我们进行了一项国际性、双中心、回顾性队列研究。采用具有时变协变量的Cox比例风险回归模型,研究肾上腺素、米力农或多巴酚丁胺是否能降低感染性休克患者的住院死亡率。使用倾向评分匹配进行敏感性分析。主要结果是住院死亡率。次要转归包括在重症监护病房(ICU)和无ICU天数内出现快速心室反应(RVR)的心房颤动(Afib)。结果:共纳入417例感染性休克患者,其中72例(17.3%)接受了肌力疗法。肾上腺素和多巴酚丁胺的使用与显著较高的住院死亡率相关(肾上腺素,危险比[HR]:4.79,95%可信区间[CI]:2.12-10.82,P=0.001;多巴酚丁胺,HR:2.53,95%可信区间:1.30-4.95,P=0.046)。肾上腺素和多巴酚丁胺的作用具有时间和剂量依赖性。米力农的使用与死亡率增加无关(HR:1.07,95%CI:0.42-2.68,P=0.345)。使用肾上腺素、多巴酚丁胺和米力农与Afib伴RVR的几率显著增加相关(肾上腺素,优势比[OR]:3.88,95%可信区间:1.11-13.61,P=.034;多巴酚丁胺,OR:3.95,95%可信区间:1.14-13.76;米力农,OR:3.77,95%可信区间:1.05-13.59)。另一方面,使用肾上腺素、多巴酚丁胺和米力农与较少的无重症监护室天数无关(肾上腺素,调整后OR:0.30,95%CI:0.09-1.01,P=0.053;多巴酚丁胺,调整后OR:0.91,95%CI:0.29-2.84;米力农,调整后OR:0.60,95%CI:0.19-1.87)。结论:本研究表明,使用肾上腺素和多巴酚丁胺与感染性休克患者的住院死亡率显著增加有关。这些效应具有时间和剂量依赖性。另一方面,米力农的使用与住院死亡率的增加无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号